A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)

被引：0
|
作者：
Bekaii-Saab, T. [1 ]
Starodub, A. [2 ,3 ]
El-Rayes, B. [4 ]
O'Neil, B. [5 ]
Shahda, S. [5 ]
Ciombor, K. [6 ]
Noonan, A. [6 ]
Hanna, W. [7 ]
Sehdev, A. [5 ]
Shaib, W. [4 ]
Mikhail, S. [6 ]
Neki, A. [6 ]
Oh, C. [8 ]
Li, Y. Z. [8 ]
Li, W. [8 ]
Borodyansky, L. [8 ]
Li, C. J. [8 ]
机构：
[1] Mayo Clin, Ctr Canc, Scottsdale, AZ USA
[2] IU Hlth Goshen Ctr Canc Care, Goshen, IN USA
[3] Parkview Hlth, Ft Wayne, IN USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] IU Hlth Univ Hosp, Indianapolis, IN USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Univ Tennessee, Med Ctr, Knoxville, TN USA
[8] Boston Biomed Inc, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA - 002
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
    Pijnappel, Esther N.
    Wassenaar, Nienke P. M.
    Gurney-Champion, Oliver J.
    Klaassen, Remy
    van der Lee, Koen
    Pleunis-van Empel, Marjolein C. H.
    Richel, Dick J.
    Legdeur, Marie C.
    Nederveen, Aart J.
    van Laarhoven, Hanneke W. M.
    Wilmink, Johanna W.
    CANCERS, 2021, 13 (19)
  • [22] Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2019, 37 : 797 - 797
  • [23] Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
    Pijnappel, E. N.
    Klaassen, R.
    van der Lee, K. S.
    Pleunis-van Empel, M.
    Richel, D.
    Legdeur, M.
    Nederveen, A.
    van Laarhoven, H. W. M.
    Wilmink, H. W.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
    Corrie, Philippa
    Qian, Wendi
    Basu, Bristi
    Valle, Juan W.
    Falk, Stephen
    Iwuji, Chinenyu
    Wasan, Harpreet Singh
    Palmer, Daniel H.
    Scott-Brown, Martin
    Wadsley, Jonathan
    Arif, Seema Safia
    Bridgewater, John A.
    Propper, David
    Gillmore, Roopinder
    Gopinathan, Aarthi
    Bax, Lisa
    Machin, Andrea
    Neesse, Albrecht
    Tuveson, David A.
    Jodrell, Duncan Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.
    O'Hara, Mark H.
    Gallagher, Maryann
    Teitelbaum, Ursina R.
    Giantonio, Bruce J.
    Damjanov, Nevena
    Loaiza-Bonilla, Arturo
    Amaravadi, Ravi K.
    Heitjan, Daniel F.
    Vasilevskaya, Irina
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    Laheru, Dan
    De Jesus-Acosta, Ana
    Velculescu, Victor E.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Phase I/II trial of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Waypa, Jordan
    Coats, Jessica
    Blaydorn, Lisa
    McGahey, Kayla
    Sangal, Ashish
    Whitehead, Robert P.
    Khemka, Vivek
    CANCER RESEARCH, 2017, 77
  • [27] Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
    Grierson, Patrick M.
    Tan, Benjamin
    Pedersen, Katrina S.
    Park, Haeseong
    Suresh, Rama
    Amin, Manik A.
    Trikalinos, Nikolaos A.
    Knoerzer, Deborah
    Kreider, Brent
    Reddy, Anupama
    Liu, Jingxia
    Der, Channing J.
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    ONCOLOGIST, 2023, 28 (02): : E115 - E123
  • [28] Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial
    Zhang, Danmei
    Westphalen, C. Benedikt
    Quante, Michael
    Waldschmidt, Dirk T.
    Held, Swantje
    Kuetting, Fabian
    Dorman, Klara
    Heinrich, Kathrin
    Weiss, Lena
    Boukovala, Myrto
    Haas, Michael
    Boeck, Stefan
    Heinemann, Volker
    Probst, Victoria
    EUROPEAN JOURNAL OF CANCER, 2024, 201
  • [29] Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study
    Yu, X.
    Shen, L.
    Hao, J.
    Wang, L.
    Pan, H.
    Han, G.
    Xu, J.
    Zhang, Y.
    Yang, S.
    Ying, J.
    Li, M.
    Begic, D.
    Lu, B.
    Xu, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 66 - 67
  • [30] A Phase II study of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer.
    Zhao, Yannan
    Lv, Fangfang
    Chen, Shen
    Lu, Yunhua
    Cao, Enying
    Wang, Zhonghua
    Zhang, Jian
    Zhang, Sheng
    Cao, Jun
    Zheng, Chunlei
    Wang, Leiping
    Wang, Biyun
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345